OVATION Receives Fast Track Designation for Sabril to Treat Cocaine and Methamphetamine Dependence

OVATION Pharmaceuticals, Inc. announced today that Sabril(R) (vigabatrin) has received Fast Track designation from the U.S. Food and Drug Administration (FDA), potentially expediting development of this novel compound that is being evaluated for the treatment of cocaine and methamphetamine dependence. Fast Track status indicates that the FDA has recognized that Sabril is intended for the treatment of a serious or life-threatening condition for which there are no available treatments and which demonstrates the potential to address unmet medical needs.